329 related articles for article (PubMed ID: 22648780)
21. Animal models for prenatal gene therapy: the nonhuman primate model.
Mattar CN; Biswas A; Choolani M; Chan JK
Methods Mol Biol; 2012; 891():249-71. PubMed ID: 22648776
[TBL] [Abstract][Full Text] [Related]
22. Murine leukemia following irradiation conditioning for transplantation of lentivirally-modified hematopoietic stem cells.
Siapati EK; Bigger BW; Kashofer K; Themis M; Thrasher AJ; Bonnet D
Eur J Haematol; 2007 Apr; 78(4):303-13. PubMed ID: 17378892
[TBL] [Abstract][Full Text] [Related]
23. Long-term transgene expression by administration of a lentivirus-based vector to the fetal circulation of immuno-competent mice.
Waddington SN; Mitrophanous KA; Ellard FM; Buckley SM; Nivsarkar M; Lawrence L; Cook HT; Al-Allaf F; Bigger B; Kingsman SM; Coutelle C; Themis M
Gene Ther; 2003 Aug; 10(15):1234-40. PubMed ID: 12858188
[TBL] [Abstract][Full Text] [Related]
24. In vivo silencing of the human gamma-globin gene in murine erythroid cells following retroviral transduction.
Lung HY; Meeus IS; Weinberg RS; Atweh GF
Blood Cells Mol Dis; 2000 Dec; 26(6):613-9. PubMed ID: 11358353
[TBL] [Abstract][Full Text] [Related]
25. Restricted transgene persistence after lentiviral vector-mediated fetal gene transfer in the pregnant rabbit model.
Moreno R; Rosal M; Martinez I; Vilardell F; Gonzalez JR; Petriz J; Hernandez-Andrade E; Gratacós E; Aran JM
J Gene Med; 2008 Sep; 10(9):951-64. PubMed ID: 18613266
[TBL] [Abstract][Full Text] [Related]
26. Shuttle of lentiviral vectors via transplanted cells in vivo.
Blömer U; Gruh I; Witschel H; Haverich A; Martin U
Gene Ther; 2005 Jan; 12(1):67-74. PubMed ID: 15385952
[TBL] [Abstract][Full Text] [Related]
27. Monitoring for potential adverse effects of prenatal gene therapy: mouse models for developmental aberrations and inadvertent germ line transmission.
Coutelle C; Waddington SN; Themis M
Methods Mol Biol; 2012; 891():329-40. PubMed ID: 22648779
[TBL] [Abstract][Full Text] [Related]
28. Progress toward the genetic treatment of the beta-thalassemias.
Sadelain M; Lisowski L; Samakoglu S; Rivella S; May C; Riviere I
Ann N Y Acad Sci; 2005; 1054():78-91. PubMed ID: 16339654
[TBL] [Abstract][Full Text] [Related]
29. Insertional mutagenesis and development of malignancies induced by integrating gene delivery systems: implications for the design of safer gene-based interventions in patients.
Romano G; Marino IR; Pentimalli F; Adamo V; Giordano A
Drug News Perspect; 2009 May; 22(4):185-96. PubMed ID: 19536363
[TBL] [Abstract][Full Text] [Related]
30. Modified HIV-1 based lentiviral vectors have an effect on viral transduction efficiency and gene expression in vitro and in vivo.
Park F; Kay MA
Mol Ther; 2001 Sep; 4(3):164-73. PubMed ID: 11545606
[TBL] [Abstract][Full Text] [Related]
31. Stable and efficient intraocular gene transfer using pseudotyped EIAV lentiviral vectors.
Balaggan KS; Binley K; Esapa M; Iqball S; Askham Z; Kan O; Tschernutter M; Bainbridge JW; Naylor S; Ali RR
J Gene Med; 2006 Mar; 8(3):275-85. PubMed ID: 16299834
[TBL] [Abstract][Full Text] [Related]
32. Comparison of toxicogenomic profiles of two murine strains treated with HIV-1-based vectors for gene therapy.
Zhao Y; Keating K; Thorpe R
Toxicol Appl Pharmacol; 2007 Dec; 225(2):189-97. PubMed ID: 17904176
[TBL] [Abstract][Full Text] [Related]
33. In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo.
Okada T; Caplen NJ; Ramsey WJ; Onodera M; Shimazaki K; Nomoto T; Ajalli R; Wildner O; Morris J; Kume A; Hamada H; Blaese RM; Ozawa K
J Gene Med; 2004 Mar; 6(3):288-99. PubMed ID: 15026990
[TBL] [Abstract][Full Text] [Related]
34. Novel bovine lentiviral vectors based on Jembrana disease virus.
Metharom P; Takyar S; Xia HH; Ellem KA; Macmillan J; Shepherd RW; Wilcox GE; Wei MQ
J Gene Med; 2000; 2(3):176-85. PubMed ID: 10894263
[TBL] [Abstract][Full Text] [Related]
35. Genotoxicity in gene therapy: an account of vector integration and designer nucleases.
Bohne J; Cathomen T
Curr Opin Mol Ther; 2008 Jun; 10(3):214-23. PubMed ID: 18535928
[TBL] [Abstract][Full Text] [Related]
36. Understanding lentiviral vector chromatin targeting: working to reduce insertional mutagenic potential for gene therapy.
Papayannakos C; Daniel R
Gene Ther; 2013 Jun; 20(6):581-8. PubMed ID: 23171920
[TBL] [Abstract][Full Text] [Related]
37. Diverse genomic integration of a lentiviral vector developed for the treatment of Wiskott-Aldrich syndrome.
Mantovani J; Charrier S; Eckenberg R; Saurin W; Danos O; Perea J; Galy A
J Gene Med; 2009 Aug; 11(8):645-54. PubMed ID: 19455589
[TBL] [Abstract][Full Text] [Related]
38. Lentiviruses in gene therapy clinical research.
Connolly JB
Gene Ther; 2002 Dec; 9(24):1730-4. PubMed ID: 12457288
[TBL] [Abstract][Full Text] [Related]
39. Gene therapy progress and prospects: fetal gene therapy--first proofs of concept--some adverse effects.
Coutelle C; Themis M; Waddington SN; Buckley SM; Gregory LG; Nivsarkar MS; David AL; Peebles D; Weisz B; Rodeck C
Gene Ther; 2005 Nov; 12(22):1601-7. PubMed ID: 16136161
[TBL] [Abstract][Full Text] [Related]
40. Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells.
Recchia A; Bonini C; Magnani Z; Urbinati F; Sartori D; Muraro S; Tagliafico E; Bondanza A; Stanghellini MT; Bernardi M; Pescarollo A; Ciceri F; Bordignon C; Mavilio F
Proc Natl Acad Sci U S A; 2006 Jan; 103(5):1457-62. PubMed ID: 16432223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
